

# CITATION REPORT

List of articles citing

## Characterising the castration-resistant prostate cancer population: a systematic review

DOI: 10.1111/j.1742-1241.2011.02799.x

International Journal of Clinical Practice, 2011, 65, 1180-92.

**Source:** <https://exaly.com/paper-pdf/51002969/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
527	The three dimensional Quantitative Structure Activity Relationships (3D-QSAR) and docking studies of curcumin derivatives as androgen receptor antagonists. <b>2012</b> , 13, 6138-55		16
526	Current world literature. <b>2012</b> , 6, 402-16		
525	Healthcare resource use in advanced prostate cancer patients treated with docetaxel. <b>2012</b> , 15, 836-43		17
524	Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?. <b>2012</b> , 23 Suppl 10, x251-8		32
523	New agents for the management of castration-resistant prostate cancer. <b>2012</b> , 46, 1518-28		10
522	Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. <b>2012</b> , 57, 691-9		86
521	JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells. <b>2012</b> , 12, 130		37
520	Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database. <b>2012</b> , 36, e349-53		28
519	MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. <b>2013</b> , 377, 121-30		68
518	Targeting fibroblast growth factor pathways in prostate cancer. <b>2013</b> , 19, 5856-66		77
517	The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. <b>2013</b> , 381, 140-9		21
516	Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer. <b>2013</b> , 73, 1723-32		24
515	New platinum(II) complexes conjugated at position 7β of 17βacetyl-testosterone as new combi-molecules against prostate cancer: design, synthesis, structure-activity relationships and biological evaluation. <b>2013</b> , 68, 433-43		22
514	Fibronectin induces MMP2 expression in human prostate cancer cells. <b>2013</b> , 430, 1319-21		46
513	Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment. <b>2013</b> , 17 Suppl 1, S1-6		8
512	Recent advances in prostate development and links to prostatic diseases. <b>2013</b> , 5, 243-56		21
511	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. <b>2013</b> , 15, 342-9		23

510	Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells. <b>2013</b> , 8, e64278	31
509	Role of Par-4 in Prostate Cancer. <b>2013</b> , 481-495	1
508	Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. <b>2013</b> , 25, 406-30	34
507	Population-based study on use of chemotherapy in men with castration resistant prostate cancer. <b>2013</b> , 52, 1593-601	36
506	Current World Literature. <b>2013</b> , 23, 283-292	
505	Perspectives on treatment of metastatic castration-resistant prostate cancer. <b>2013</b> , 18, 558-67	24
504	Prostate cancer vaccines: Update on clinical development. <b>2013</b> , 2, e24523	29
503	Sequencing systemic therapies in metastatic castration-resistant prostate cancer. <b>2013</b> , 20, 181-7	8
502	Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. <b>2014</b> , 5, 133-42	6
501	Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro. <b>2014</b> , 144 Pt B, 436-44	11
500	MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients samples. <b>2014</b> , 2014, 146170	40
499	Sipuleucel-T and immunotherapy in the treatment of prostate cancer. <b>2014</b> , 14, 709-19	8
498	The effects of nonspecific HIF1 $\alpha$ inhibitors on development of castrate resistance and metastases in prostate cancer. <b>2014</b> , 3, 245-51	32
497	HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens. <b>2014</b> , 462, 315-27	15
496	Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer. <b>2014</b> , 13, 2817-26	19
495	Nonmetastatic castration-resistant prostate cancer. <b>2014</b> , 55, 153-60	21
494	Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy. <b>2014</b> , 46, 1123-9	1
493	Challenges and recommendations for early identification of metastatic disease in prostate cancer. <b>2014</b> , 83, 664-9	70

492	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <b>2014</b> , 74, 1222-30	25
491	Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer. <b>2014</b> , 74, 1521-9	43
490	Enzalutamide: looking back at its preclinical discovery. <b>2014</b> , 9, 837-45	6
489	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <b>2014</b> , 15, 1147-56	154
488	Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. <b>2014</b> , 14, 252	29
487	Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. <b>2014</b> , 74, 579-86	24
486	Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials. <b>2014</b> , 50, 1916-24	19
485	Delivery of EZH2-shRNA with mPEG-PEI nanoparticles for the treatment of prostate cancer in vitro. <b>2014</b> , 33, 1563-9	10
484	Establishing prostate cancer patient derived xenografts: lessons learned from older studies. <b>2015</b> , 75, 628-36	26
483	Prostate Cancer and Prostate Cancer Stem Cells. <b>2015</b> , 193-212	
482	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. <b>2015</b> , 9, 31-8	19
481	Development of enzalutamide for metastatic castration-resistant prostate cancer. <b>2015</b> , 1358, 13-27	8
480	Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. <b>2015</b> , 5, 129	6
479	Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain. <b>2015</b> , 2015, 186740	4
478	Sequencing of agents in castration-resistant prostate cancer. <b>2015</b> , 16, e279-92	123
477	Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. <b>2015</b> , 14, 1127-36	13
476	Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine. <b>2015</b> , 38, 654-68	3
475	Integrin $\beta$ and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance. <b>2015</b> , 47, 384-90	66

474	Cadmium exposure inhibits MMP2 and MMP9 activities in the prostate and testis. <b>2015</b> , 457, 538-41	20
473	Management and characteristics of patients with metastatic prostate cancer in a cohort of New Zealand men. <b>2015</b> , 88, 157-63	3
472	Melampodium leucanthum, a source of cytotoxic sesquiterpenes with antimetabolic activities. <b>2015</b> , 78, 388-95	10
471	Metastatic castration-resistant prostate cancer: time for innovation. <b>2015</b> , 11, 91-106	22
470	An update on enzalutamide in the treatment of prostate cancer. <b>2015</b> , 7, 9-21	29
469	Öryzanol reduces caveolin-1 and PCGEM1 expression, markers of aggressiveness in prostate cancer cell lines. <b>2015</b> , 75, 783-97	15
468	Molecular landscape of prostate cancer: implications for current clinical trials. <b>2015</b> , 41, 761-6	42
467	Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer. <b>2015</b> , 33, 385.e15-20	57
466	Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. <b>2015</b> , 13, 620-635	31
465	Current role of cabozantinib in metastatic castration-resistant prostate cancer. <b>2015</b> , 15, 151-6	8
464	NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer. <b>2015</b> , 16, 369-70	6
463	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <b>2015</b> , 16, 509-21	138
462	Extracting the Benefit of Nexrutine for Cancer Prevention. <b>2015</b> , 1, 365-372	10
461	Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. <b>2015</b> , 4, 387-402	9
460	Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. <b>2015</b> , 28, 500-514	121
459	Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. <b>2016</b> , 22, 163-70	16
458	Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. <b>2016</b> , 8, 217-224	4
457	The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients. <b>2016</b> , 57, 174-83	12

456	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeutics. <b>2016</b> , 6, 1085-95	50
455	Knockdown of GPR137, G Protein-coupled receptor 137, Inhibits the Proliferation and Migration of Human Prostate Cancer Cells. <b>2016</b> , 87, 704-13	6
454	Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. <b>2016</b> , 6, e010332	25
453	Oncolytic virotherapy for urological cancers. <b>2016</b> , 13, 334-52	12
452	Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells. <b>2016</b> , 11, 1207-22	26
451	Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. <b>2016</b> , 2, 540-546	21
450	Radium-223 Therapy of Bone Metastases in Prostate Cancer. <b>2016</b> , 46, 544-556	7
449	Therapeutic management of bone metastasis in prostate cancer: an update. <b>2016</b> , 16, 1199-1211	6
448	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. <b>2016</b> , 16, 1113-1120	5
447	PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. <b>2016</b> , 57, 97S-104S	122
446	Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración. <b>2016</b> , 76, 288-293	
445	Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. <b>2016</b> , 117, 215-25	66
444	Androgen deprivation modulates gene expression profile along prostate cancer progression. <b>2016</b> , 56, 81-8	19
443	TRIM-ing Ligand Dependence in Castration-Resistant Prostate Cancer. <b>2016</b> , 29, 776-778	5
442	Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. <b>2016</b> , 10, 693-703	33
441	Texas Native Plants Yield Compounds with Cytotoxic Activities against Prostate Cancer Cells. <b>2016</b> , 79, 531-40	24
440	Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. <b>2016</b> , 34, 1505-1513	14
439	Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from (223)Ra-dichloride to new horizons for therapeutic response assessment. <b>2016</b> , 43, 5-7	5

438	Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. <b>2016</b> , 19, 111-21	44
437	<b>177Lu</b> -Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. <b>2016</b> , 57, 1006-13	331
436	Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. <b>2016</b> , 43, 1546-62	32
435	Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. <b>2016</b> , 15, 1353-63	12
434	A selective alpha1D-adrenoreceptor antagonist inhibits human prostate cancer cell proliferation and motility "in vitro". <b>2016</b> , 103, 215-26	8
433	Incidence and Correlates of Fatigue in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review. <b>2016</b> , 14, 5-11	10
432	Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. <b>2017</b> , 4, 37-43	30
431	Prostate Cancer Metastasis. <b>2017</b> , 33-59	1
430	Navigating the evolving therapeutic landscape in advanced prostate cancer. <b>2017</b> , 35S, S1-S13	46
429	Selective anti-proliferative activities of <i>Carica papaya</i> leaf juice extracts against prostate cancer. <b>2017</b> , 89, 515-523	27
428	Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. <b>2017</b> , 22, 954-963	6
427	Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer. <b>2017</b> , 17, 316	56
426	Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. <b>2017</b> , 20, 352-360	53
425	Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. <b>2017</b> , 15, 520-525	7
424	Post-therapeutic dosimetry of <b>177Lu</b> -DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. <b>2017</b> , 38, 91-98	43
423	Emerging Variants of Castration-Resistant Prostate Cancer. <b>2017</b> , 19, 32	86
422	Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment. <b>2017</b> , 39, 723-737	19
421	The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use. <b>2017</b> , 17, 511-517	4

4 <sup>20</sup>	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. <b>2017</b> , 15, 610-617.e3	18
4 <sup>19</sup>	Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?. <b>2017</b> , 44, 611-621	31
4 <sup>18</sup>	Prostate cancer xenografts and hormone induced prostate carcinogenesis. <b>2017</b> , 97, 23-32	9
4 <sup>17</sup>	A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. <b>2017</b> , 19, 915-922	8
4 <sup>16</sup>	Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era. <b>2017</b> , 7, 601-603	3
4 <sup>15</sup>	Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. <b>2017</b> , 198, 1324-1332	6
4 <sup>14</sup>	Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. <b>2017</b> , 80, 1063-1072	15
4 <sup>13</sup>	Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. <b>2017</b> , 10, 809-819	2
4 <sup>12</sup>	Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness. <b>2017</b> , 11, 247-260	28
4 <sup>11</sup>	Phase I/II trials of Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival. <b>2017</b> , 44, 620-629	13
4 <sup>10</sup>	Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. <b>2017</b> , 44, 81-91	109
4 <sup>09</sup>	Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. <b>2017</b> , 20, 121-128	16
4 <sup>08</sup>	Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. <b>2017</b> , 123, 253-262	26
4 <sup>07</sup>	Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. <b>2017</b> , 80, 1073-1077	1
4 <sup>06</sup>	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. <b>2017</b> ,	3
4 <sup>05</sup>	Does T1- and diffusion-weighted magnetic resonance imaging give value-added than bone scintigraphy in the follow-up of vertebral metastasis of prostate cancer?. <b>2017</b> , 58, 324-330	3
4 <sup>04</sup>	Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. <b>2017</b> , 23, 416-426	8
4 <sup>03</sup>	Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. <b>2017</b> , 8, 3724-3745	71



402	Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study. <b>2017</b> , 24, 240-248	5
401	Anticoagulants Could Be a Victim of Enzalutamide. <b>2017</b> , 13, 730-731	
400	Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. <b>2017</b> , 35, 1952-1964	35
399	Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion Summary. <b>2017</b> , 13, 459-461	5
398	Castration-Resistant Prostate Cancer. <b>2018</b> , 297-322	
397	The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. <b>2018</b> , 200, 344-352	37
396	Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. <b>2018</b> , 10, 1758834017745819	11
395	Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer. <b>2018</b> , 2018, omx078	7
394	Immune-based therapies for metastatic prostate cancer: an update. <b>2018</b> , 10, 283-298	7
393	Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. <b>2018</b> , 78, 435-445	16
392	Prostate cancer-associated lncRNAs. <b>2018</b> , 418, 159-166	49
391	Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. <b>2018</b> , 46, 1895-1911	51
390	Up-regulated miR-29c inhibits cell proliferation and glycolysis by inhibiting SLC2A3 expression in prostate cancer. <b>2018</b> , 665, 26-34	18
389	New horizons in the management of castrate-resistant prostate cancer. <b>2018</b> , 11, 258-265	2
388	Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes. <b>2018</b> , 423, 28-35	11
387	Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. <b>2018</b> , 16, e411-e419	25
386	Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer. <b>2017</b> ,	
385	Hydroalcoholic extract of the widely used Mexican plant <i>Justicia spicigera</i> Schltdl. exerts a cytostatic effect on LNCaP prostate cancer cells. <b>2018</b> , 12, 66-72	3

384	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. <b>2018</b> , 25, R83-R113	11
383	Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells. <b>2018</b> , 78, 64-75	28
382	Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials. <b>2018</b> , 97, e13204	3
381	Development of Oncolytic Adenoviruses for the Management of Prostate Cancer. <b>2018</b> ,	1
380	Three May Be Better Than Two: A Proposal for Metformin Addition to PI3K/Akt Inhibitor-antiandrogen Combination in Castration-resistant Prostate Cancer. <b>2018</b> , 10, e3403	3
379	Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). <b>2017</b> , 2, 27	9
378	Management of nonmetastatic castration-resistant prostate cancer. <b>2018</b> , 12, 366-371	1
377	Human ex vivo 3D bone model recapitulates osteocyte response to metastatic prostate cancer. <b>2018</b> , 8, 17975	20
376	Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity. <b>2018</b> , 42, 616-624	
375	Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. <b>2018</b> , 13, e0208063	14
374	Affinity-Driven Covalent Modulator of the Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Cascade. <b>2018</b> , 130, 7158-7163	1
373	Expression patterns and bioinformatic analysis of miR-1260a and miR-1274a in Prostate Cancer Tunisian patients. <b>2018</b> , 45, 2345-2358	10
372	Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. <b>2018</b> , 1096, 117-133	24
371	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. <b>2018</b> , 10, CD012816 <sub>12</sub>	
370	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. <b>2018</b> , 214, 1675-1680	1
369	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. <b>2018</b> , 18, 77	1
368	Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis. <b>2018</b> , 35, 1639-1655	14
367	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. <b>2018</b> , 4, 944-951	50

366	Molecular Subtypes of Prostate Cancer. <b>2018</b> , 20, 58	45
365	Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. <b>2018</b> , 104, 128-136	11
364	The dialyzable leukocyte extract Transferon inhibits tumor growth and brain metastasis in a murine model of prostate cancer. <b>2018</b> , 101, 938-944	10
363	High SRPX2 protein expression predicts unfavorable clinical outcome in patients with prostate cancer. <b>2018</b> , 11, 3149-3157	6
362	Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity. <b>2018</b> , 42, 616-624	
361	Profiling Prostate Cancer Therapeutic Resistance. <b>2018</b> , 19,	59
360	Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. <b>2018</b> , 45, 2264-2273	12
359	External radiation exposure, excretion, and effective half-life in Lu-PSMA-targeted therapies. <b>2018</b> , 8, 32	18
358	Microsatellite instability in prostate cancer by PCR or next-generation sequencing. <b>2018</b> , 6, 29	58
357	Affinity-Driven Covalent Modulator of the Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Cascade. <b>2018</b> , 57, 7040-7045	5
356	Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer. <b>2018</b> , 16, 133-143	6
355	Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer. <b>2018</b> , 14, 2383-2401	4
354	High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer. <b>2018</b> , 16, 297-319	4
353	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. <b>2018</b> , 24, 4662-4671	15
352	Options After Chemotherapy for Patients with Metastatic, Castration-Resistant Prostate Cancer. <b>2018</b> , 121-134	
351	The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. <b>2018</b> , 56, 133-140	7
350	An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). <b>2019</b> , 123, 456-464	9
349	First-in-human study of Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. <b>2019</b> , 46, 148-158	43

348	Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene and lncRNA in Prostate Cancer. <b>2019</b> , 8,	21
347	Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor. <b>2019</b> , 105, 376-381	28
346	Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data. <b>2019</b> , 22, 1080-1087	2
345	Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer. <b>2019</b> , 15, 288-295	4
344	The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer. <b>2019</b> , 8, 5202-5213	24
343	Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer. <b>2019</b> , 79, 1811-1822	3
342	Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines. <b>2019</b> , 20,	3
341	Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. <b>2019</b> , 22, 1202-1209	12
340	Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor. <b>2019</b> , 17, 364-386	1
339	Melatonin and Docosahexaenoic Acid Decrease Proliferation of PNT1A Prostate Benign Cells via Modulation of Mitochondrial Bioenergetics and ROS Production. <b>2019</b> , 2019, 5080798	14
338	Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <b>2019</b> , 195, 872-881	7
337	Clinical Outcomes of Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. <b>2019</b> , 60, 955-962	57
336	Prognostic Value of F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel. <b>2019</b> , 2019, 4325946	1
335	HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer. <b>2019</b> , 11, 283-300	4
334	Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. <b>2019</b> , 8,	10
333	Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. <b>2019</b> , 25, 889-897	3
332	The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan. <b>2019</b> , 35, 1745-1750 <sup>15</sup>	15
331	BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK. <b>2019</b> , 17, 1627-1638	20

330	Radioligand Therapy With Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <b>2019</b> , 213, 275-285	80
329	Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. <b>2019</b> , 22, 522-530	9
328	Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases. <b>2019</b> , 25, S1-S11	6
327	Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence. <b>2019</b> , 105, 277-281	5
326	Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. <b>2019</b> , 15, 1437-1457	13
325	Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney. <b>2019</b> , 60, 1579-1586	19
324	[Chemohormonal therapy for metastatic prostate cancer : Taxane-based approaches]. <b>2019</b> , 58, 428-431	
323	Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with F-FDG PET/CT. <b>2019</b> , 60, 1524-1530	14
322	Expression and Localization of DDX3 in Prostate Cancer Progression and Metastasis. <b>2019</b> , 189, 1256-1267	7
321	TGF- $\beta$ Receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. <b>2019</b> , 79, 31-43	29
320	Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells. <b>2019</b> , 79, 720-731	4
319	A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer. <b>2019</b> , 9, e274-e282	3
318	Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. <b>2019</b> , 6, 82-90	17
317	Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre study. <b>2019</b> , 49, 1378-1385	4
316	Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity. <b>2019</b> , 8, 519-528	9
315	Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer. <b>2019</b> , 15, e510-e519	0
314	New developments in mechanisms of prostate cancer progression. <b>2019</b> , 57, 111-116	24
313	Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer. <b>2019</b> , 28, e12949	6

312	Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications. <b>2019</b> , 30, 366-383	88
311	SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. <b>2019</b> , 193, 217-229	12
310	Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews. <b>2019</b> , 12, 57-67	11
309	Metastatic prostate cancer remains incurable, why?. <b>2019</b> , 6, 26-41	58
308	Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. <b>2019</b> , 21, 420-432	3
307	Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. <b>2019</b> , 22, 252-260	12
306	Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1. <b>2019</b> , 192, 105115	11
305	ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. <b>2020</b> , 6, 63-70	3
304	Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review. <b>2020</b> , 38, 613-635	9
303	Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. <b>2020</b> , 43, 23-33	2
302	A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use. <b>2020</b> , 4, 439-447	5
301	Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study. <b>2020</b> , 77, 380-387	20
300	Understanding symptomatic experience, impact, and emotional response in recently diagnosed metastatic castration-resistant prostate cancer: a qualitative study. <b>2020</b> , 28, 3093-3101	7
299	Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. <b>2020</b> , 18, e180-e189	11
298	New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. <b>2020</b> , 47, 687-694	22
297	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <b>2020</b> , 18, e233-e253	1
296	METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer. <b>2020</b> , 18, e391-e396	8
295	Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study. <b>2020</b> , 8, 34-40	7

294	From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer. <b>2020</b> , 74, 23-36	16
293	Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan. <b>2020</b> , 15, 635-643	4
292	A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. <b>2020</b> , 37, 4910-4929	5
291	Development and prevalence of castration-resistant prostate cancer subtypes. <b>2020</b> , 22, 566-575	16
290	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells. <b>2020</b> , 28, 115712	5
289	Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion. <b>2020</b> , 39, 5690-5707	3
288	NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs. <b>2020</b> , 12,	3
287	The prognostic value and potential mechanism of Matrix Metalloproteinases among Prostate Cancer. <b>2020</b> , 17, 1550-1560	6
286	Liquid Biopsy to Detect DNA/RNA Based Markers of Small DNA Oncogenic Viruses for Prostate Cancer Diagnosis, Prognosis, and Prediction. <b>2020</b> , 10, 778	5
285	Docosahexaenoic acid differentially modulates the cell cycle and metabolism- related genes in tumor and pre-malignant prostate cells. <b>2020</b> , 1865, 158766	3
284	Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer. <b>2020</b> , 39, 5839-5854	5
283	RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance. <b>2020</b> , 117, 28092-28101	8
282	Lutetium-177-PSMA therapy for prostate cancer patients—brief overview of the literature. <b>2020</b> , 10, 141-146	3
281	Aggressive prostate cancer phenotype and genome-wide association studies: where are we now?. <b>2020</b> , 21, 487-503	1
280	CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone. <b>2020</b> , 86, 527-533	5
279	Long Non-Coding Small Nucleolar RNA Host Genes (SNHG) in Endocrine-Related Cancers. <b>2020</b> , 13, 7699-7717	13
278	Metabolic Roles of Androgen Receptor and Tip60 in Androgen-Dependent Prostate Cancer. <b>2020</b> , 21,	3
277	A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer. <b>2020</b> , 93, 20200775	0

276	Genistein Combined Polysaccharide (GCP) Can Inhibit Intracrine Androgen Synthesis in Prostate Cancer Cells. <b>2020</b> , 8,	4
275	LncRNA binds HSP90 to promote the proliferation of prostate cancer. <b>2020</b> , 12, 1257-1271	10
274	Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer. <b>2020</b> , 61, 1772-1778	7
273	Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: A protocol of systematic review and meta-analysis. <b>2020</b> , 99, e20297	1
272	Independence of HIF1a and androgen signaling pathways in prostate cancer. <b>2020</b> , 20, 469	8
271	A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy. <b>2020</b> , 10, 8191	4
270	Identification of castration-resistant prostate cancer-related hub genes using weighted gene co-expression network analysis. <b>2020</b> , 24, 8006-8017	9
269	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. <b>2020</b> , 12,	22
268	Long non-coding RNA FER1L4 inhibits prostate cancer progression via sponging miR-92a-3p and upregulation of FBXW7. <b>2020</b> , 20, 64	11
267	The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression. <b>2020</b> , 13, 100751	8
266	Suppression of TRPM7 Inhibited Hypoxia-Induced Migration and Invasion of Androgen-Independent Prostate Cancer Cells by Enhancing RACK1-Mediated Degradation of HIF-1. <b>2020</b> , 2020, 6724810	7
265	Exosomes are the Driving Force in Preparing the Soil for the Metastatic Seeds: Lessons from the Prostate Cancer. <b>2020</b> , 9,	27
264	LncRNA promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. <b>2020</b> , 12, 1123-1138	7
263	Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. <b>2020</b> , 9,	1
262	and Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells. <b>2020</b> , 17, 496-507	2
261	Overall survival and second primary malignancies in men with metastatic prostate cancer. <b>2020</b> , 15, e0227552	8
260	Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. <b>2020</b> , 37, 2083-2097	4
259	A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. <b>2020</b> , 18, 171-178.e2	10



258	How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study. <b>2020</b> , 80, 432-440	4
257	β-Tocotrienol and β-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells. <b>2020</b> , 25,	6
256	Prostate Cancer in Latin America: Challenges and Recommendations. <b>2020</b> , 27, 1073274820915720	1
255	NF-Β signaling promotes castration-resistant prostate cancer initiation and progression. <b>2020</b> , 211, 107538	11
254	Characterization of the prognostic values and response to immunotherapy/chemotherapy of Krppel-like factors in prostate cancer. <b>2020</b> , 24, 5797-5810	7
253	Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. <b>2020</b> , 12,	1
252	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. <b>2020</b> , 99, e19760	18
251	Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing Lu-PSMA-617 radioligand therapy. <b>2021</b> , 48, 103-112	13
250	Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study. <b>2021</b> , 5, 299-310	2
249	Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer. <b>2021</b> , 27, 166-174	2
248	Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. <b>2021</b> , 24, 301-309	7
247	Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. <b>2021</b> , 24, 244-252	3
246	M0CRPC overview of management options. <b>2021</b> , 39, 349-356	5
245	Evolution of Androgenic Deprivation in Treatment of Prostate Cancer in Kinshasa. <b>2021</b> , 11, 137-157	1
244	PDA Indolylmaleimides Induce Anti-Tumor Effects in Prostate Carcinoma Cell Lines Through Mitotic Death. <b>2020</b> , 7, 558135	2
243	Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience. <b>2021</b> , 16, 5	2
242	Recent Developments and Applications of Quantitative Proteomics Strategies for High-Throughput Biomolecular Analyses in Cancer Research. <b>2021</b> , 4, 1050-1072	2
241	Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer Recurrence Revealed by Choline PET/CT. <b>2021</b> , 14, 13-16	

240	Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. <b>2021</b> , 4, e2033787	0
239	Alternol triggers immunogenic cell death reactive oxygen species generation. <b>2021</b> , 10, 1952539	7
238	Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. <b>2021</b> , 9,	19
237	Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. <b>2021</b> , 13,	5
236	Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients. <b>2021</b> , 18, 284-294	1
235	Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel. <b>2021</b> , 13,	1
234	Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. <b>2021</b> , 11,	2
233	p38 MAPK Inhibition Mitigates Hypoxia-Induced AR Signaling in Castration-Resistant Prostate Cancer. <b>2021</b> , 13,	3
232	Căncer de prōstata. <b>2021</b> , 13, 1454-1466	
231	Eupatilin Inhibits the Proliferation and Migration of Prostate Cancer Cells through Modulation of PTEN and NF- $\kappa$ B Signaling. <b>2021</b> , 21, 372-382	4
230	Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer. <b>2021</b> , 13,	7
229	A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy. <b>2021</b> , 10, 954-962	2
228	Pain Biomarkers in Cancer: An Overview. <b>2021</b> , 27, 293-304	0
227	The Real-World Experience of Single-Center, Retrospective Study of the Prognostic Effect of Secondary Hormone Agent on Survival in Patients With Hormone-Refractory Metastatic Prostate Cancer. <b>2021</b> , 19, 48-59	
226	Combination of Platycodin D with docetaxel synergistically suppressed cell growth in DU-145 by enhancing apoptosis and alleviating autophagy. <b>2021</b> , 42, 101302	0
225	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. <b>2021</b> , 27, 3360-3369	17
224	Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. <b>2021</b> , 24, 323-334	5
223	Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis targeted agents. <b>2021</b> , 26, 753-763	0

222	Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer. <b>2020</b> , 10, 594141	1
221	Stereotactic radiotherapy to oligoprogressive lesions detected with Ga-PSMA-PET/CT in castration-resistant prostate cancer patients. <b>2021</b> , 48, 3683-3692	9
220	Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. <b>2021</b> , 12, 1714	19
219	Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor. <b>2021</b> , 22,	4
218	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. <b>2021</b> , 10, 1562-1568	1
217	The inhibitory effect of melatonin on human prostate cancer. <b>2021</b> , 19, 34	8
216	Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician perception according to patient comorbidities. <b>2021</b> , 47, 359-373	0
215	Androgen Receptor-Related Non-coding RNAs in Prostate Cancer. <b>2021</b> , 9, 660853	5
214	Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. <b>2021</b> , 9,	3
213	Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [Lu]Lu-PSMA-617. <b>2021</b> , 64, 4960-4971	5
212	Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. <b>2021</b> , 81, 543-552	9
211	[Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program]. <b>2021</b> ,	
210	Novel approaches to target the microenvironment of bone metastasis. <b>2021</b> , 18, 488-505	16
209	Hypothesis: The triad androgen receptor, zinc finger proteins and telomeres modulates the global gene expression pattern during prostate cancer progression. <b>2021</b> , 150, 110566	1
208	Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report. <b>2021</b> , 22, e930989	0
207	Serum testosterone levels and testosterone bounce phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer. <b>2021</b> , 39, 829.e9-829.e17	1
206	Competition (Steal Phenomenon) between [Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue. <b>2021</b> , 13,	1
205	Comparison of different methods for post-therapeutic dosimetry in [Lu]Lu-PSMA-617 radioligand therapy. <b>2021</b> , 8, 40	3

204	A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer. <b>2021</b> , 11, 675215	0
203	Efficacy and Safety of [Ac]Ac-PSMA-617 Augmented [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. <b>2021</b> , 13,	8
202	Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer. <b>2021</b> , 9,	2
201	Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis. <b>2021</b> , 32, 363-377	2
200	Anti-Tumor Effects of Ginsenoside 20(S)-Protopanaxadiol and 1,25-Dihydroxyvitamin D3 Combination in Castration Resistant Prostate Cancer. <b>2021</b> , 8,	
199	Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. <b>2021</b> , 21, 655	1
198	Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer. <b>2021</b> , 88, 525-531	0
197	AR-mTOR-SRF Axis Regulates HMMR Expression in Human Prostate Cancer Cells. <b>2021</b> , 29, 667-677	1
196	Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. <b>2021</b> , 39, 367.e7-367.e17	0
195	Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study. <b>2021</b> , 19, e171-e177	
194	A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. <b>2021</b> , 22, 1685-1728	1
193	Exploring Nanoemulsions for Prostate Cancer Therapy. <b>2021</b> , 71, 417-428	0
192	[Metastatic castration-resistant prostate cancer]. <b>2021</b> , 42, 431-441	1
191	Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. <b>2021</b> , 13,	3
190	Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. <b>2021</b> , 38, 4520-4540	1
189	Predictive Biomarkers of Dicycloplatin Resistance or Susceptibility in Prostate Cancer. <b>2021</b> , 12, 669605	0
188	MicroRNA-1205 Regulation of FRYL in Prostate Cancer. <b>2021</b> , 9, 647485	1
187	An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. <b>2021</b> , 12, 4601	4

186	Response Assessment and Prediction of Progression-Free Survival by Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing Lu-PSMA-617 Radioligand Therapy. <b>2021, 11,</b>	2
185	Value of Combined PET Imaging with [F]FDG and [Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [Lu]Lu-PSMA-617 RLT. <b>2021, 13,</b>	5
184	PSMA Theranostics: Current Landscape and Future Outlook. <b>2021, 13,</b>	10
183	Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines. <b>2021, 16, e0256468</b>	
182	Procalcitonina. Utilidad como biomarcador en el diagnóstico de tumores neuroendocrinos. <b>2021, 6, 21-23</b>	
181	Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis. <b>2021,</b>	8
180	Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance. <b>2021, 11, 17157</b>	
179	Salvage Radioligand Therapy with Repeated Cycles of Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement. <b>2021, 13,</b>	1
178	Update on radioligand therapy with Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. <b>2021, 3008916211037732</b>	0
177	The Multifaceted Role of Aldehyde Dehydrogenases in Prostate Cancer Stem Cells. <b>2021, 13,</b>	4
176	Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer. <b>2021, 22,</b>	8
175	LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance. <b>2021, 12, 856</b>	3
174	Prognostic value of TERF1 expression in prostate cancer. <b>2021, 33, 24</b>	1
173	Molecular imaging and biochemical response assessment after a single cycle of [Ac]Ac-PSMA-617/[Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [Lu]Lu-PSMA-617 monotherapy. <b>2021, 11, 4050-4060</b>	16
172	MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer. <b>2021, 11, 5794-5812</b>	8
171	Hormonal Therapy for Prostate Cancer. <b>2021, 42, 354-373</b>	18
170	Cancer Stem Cells Provide New Insights into the Therapeutic Responses of Human Prostate Cancer. <b>2013, 51-75</b>	1
169	Neural Transcription Factors in Disease Progression. <b>2019, 1210, 437-462</b>	2

168	3D porous chitosan-chondroitin sulfate scaffolds promote epithelial to mesenchymal transition in prostate cancer cells. <b>2020</b> , 254, 120126	13
167	Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population. <b>2021</b> , 51, 639-645	1
166	Immune Response Drives Outcomes in Prostate Cancer: Implications for Immunotherapy.	0
165	Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy. <b>2018</b> , 2018,	3
164	Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial. <b>2020</b> , 20, 457	3
163	Neuron-specific enolase has potential value as a biomarker for [F]FDG/[Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. <b>2020</b> , 10, 52	8
162	Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients. <b>2016</b> , 5, 2676	14
161	Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients. 5, 2676	2
160	Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients. <b>2016</b> , 5, 2676	10
159	The role of hypoxia-inducible factor 1 $\alpha$ n determining the properties of castrate-resistant prostate cancers. <b>2013</b> , 8, e54251	56
158	A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. <b>2015</b> , 10, e0117002	13
157	Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence. <b>2020</b> , 15, e0242970	3
156	Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR. <b>2019</b> , 26, 147-162	4
155	SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES. <b>2018</b> , 14, 120-127	2
154	Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. <b>2020</b> , 26, 538-549	6
153	Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer. <b>2017</b> , 8, 114845-114855	12
152	Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme. <b>2019</b> , 10, 4161-4168	5
151	Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. <b>2015</b> , 6, 35542-55	53

150	Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. <b>2016</b> , 7, 38551-38565	25
149	High expression of citron kinase predicts poor prognosis of prostate cancer. <b>2020</b> , 19, 1815-1823	4
148	GRB2-associated binding protein 2 regulates multiple pathways associated with the development of prostate cancer. <b>2020</b> , 20, 99	2
147	CoMFA, CoMSIA, HQSAR and Molecular Docking Analysis of Ionone-based Chalcone Derivatives as Antiprostate Cancer Activity. <b>2016</b> , 78, 54-64	13
146	Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study. <b>2018</b> , 20, 545-550	5
145	New Molecular Targets in Metastatic Prostate Cancer. <b>2016</b> , 07, 388-401	1
144	Prevalence of Castration Success Rate in Iranian Metastatic Prostate Cancer Patients -A Referral Center Statistics. <b>2018</b> , In Press,	4
143	Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach. <b>2021</b> , 26,	1
142	AK-I-190, a New Catalytic Inhibitor of Topoisomerase II with Anti-Proliferative and Pro-Apoptotic Activity on Androgen-Negative Prostate Cancer Cells. <b>2021</b> , 22,	2
141	Novel chemotherapeutic agent FX-9 activates NF- $\kappa$ B signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line. <b>2021</b> , 21, 1088	
140	Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies. <b>2021</b> , 12, 732266	4
139	Real-World Treatment Patterns in Men with Castration-Resistant Prostate Cancer Receiving Docetaxel. <b>2014</b> , 2, 119-130	
138	Approaches for Assessment of Response of Bone Metastases to Therapies. <b>2017</b> , 223-249	
137	Bone Metastases from Prostate Cancer: Hormonal Therapy. <b>2017</b> , 105-120	
136	Markers of Prostate Cancer: The Role of Circulating Tumor Markers in the Management of Bone Metastases. <b>2017</b> , 33-45	
135	Near Complete Response to <sup>177</sup> Lu-PSMA-DKFZ-617 Therapy in a Patient with Metastatic Castration Resistant Prostate Cancer. <b>2017</b> , 1, 083-086	
134	Better Late than Never: How the U.S. Government Can and Should Use Bayh-Dole March-In Rights to Respond to the Medicines Access Crisis.	
133	Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data. <b>2018</b> , 13, 91-100	

- 132 Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy. **2018**, 19, 61-63
- 131 CASTRATION-RESISTANT PROSTATE CANCER: NEW PERSPECTIVES IN PHARMACOLOGICAL TREATMENT. **2019**, 25, 49-58 1
- 130 Modern drug therapy of prostate cancer through the example of Moscow. **2019**, 15, 77-85 1
- 129 Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. **2019**, 15, 86-99 1
- 128 Independence of HIF1a and androgen signaling pathways in prostate cancer.
- 127 Management of Patients With Advanced Prostate Cancer: Establishment of Treatment Guidelines Through Prostate Cancer Summit (PCAS) 2016 Composed of Korean Prostate Cancer Experts. **2020**, 18, 124-139
- 126 Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?. **2021**, 10, 2
- 125 Optimierung der <sup>223</sup>Radium-Dichlorid-Therapie von Patienten mit kastrationsresistentem Prostatakarzinom und Knochenmetastasen. **2021**, 16, 494
- 124 Early molecular imaging response assessment based on determination of total viable tumor burden in [Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [Lu]Lu-PSMA-617 radioligand therapy. **2021**, 1 2
- 123 LncRNAs in the Development, Progression, and Therapy Resistance of Hormone-Dependent Cancer. **2020**, 255-276
- 122 Development of an Albumin-Based PSMA Probe With Prolonged Half-Life. **2020**, 7, 585024 1
- 121 Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a. **2021**, 81, 147-156 8
- 120 Association between the anticancer efficacy of cabazitaxel and toll-like receptor 4 mediating signaling pathways in metastatic castration-resistant prostate cancer cells. **2021**, 40, 1122-1129 2
- 119 Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment. **2020**, 1296, 183-198 0
- 118 Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
- 117 Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. **2021**,
- 116 An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. **2020**, 16, 90-101 1
- 115 Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases. **2013**, 6, 307-16 8



114	KLK-targeted Therapies for Prostate Cancer. <b>2014</b> , 25, 207-18	6
113	Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy. <b>2017</b> , 10, 143-153	16
112	Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. <b>2019</b> , 11, 1255-1269	12
111	Nicosamide exerts anticancer effects through inhibition of the FOXM1-mediated DNA damage response in prostate cancer. <b>2021</b> , 11, 2944-2959	1
110	Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor- $\beta$ . <b>2021</b> , 288, 120171	1
109	The relationship between $^{68}\text{Ga}$ -PSMA uptake and Gleason Score and PSA levels in patients with prostate cancer. <b>2021</b> , 3, 327-332	
108	Exploring the Value of as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer.. <b>2021</b> , 11,	0
107	Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide. <b>2021</b> , 1	0
106	Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity. <b>2021</b> , 11,	1
105	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.. <b>2022</b> ,	11
104	Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKC $\delta$ .. <b>2022</b> ,	0
103	Cáncer de próstata resistente a la castración no metastásico: recomendaciones de manejo. <b>2022</b> ,	
102	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer.. <b>2022</b> , 14,	3
101	A Post-Marketing Surveillance Study to Evaluate the Safety Profile of Alvotere (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy.. <b>2022</b> , 96, 100659	0
100	Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer.. <b>2022</b> ,	0
99	Mucinous metaplasia in Pten conditional knockout mice and mucin family genes as prognostic markers for prostate cancer.. <b>2022</b> , 293, 120264	1
98	PP2A promotes apoptosis and facilitates docetaxel sensitivity via the PP2A/p-eIF4B/XIAP signaling pathway in prostate cancer.. <b>2022</b> , 23, 101	0
97	Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma-Progress and Challenges.. <b>2022</b> , 10,	1

96	Histone deacetylase inhibitor sodium butyrate regulates the activation of toll-like receptor 4/interferon regulatory factor-3 signaling pathways in prostate cancer cells. <b>2022,</b>	0
95	Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers.. <b>2022, 14,</b>	1
94	Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.. <b>2022, 10,</b>	4
93	Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better.. <b>2022,</b>	
92	OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR.. <b>2022, 5, 182</b>	2
91	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC.. <b>2022, 14,</b>	1
90	Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.. <b>2022, 14, e22942</b>	0
89	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.. <b>2022, 1</b>	
88	Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis.. <b>2022, 28, 287-295</b>	
87	Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan.. <b>2022, 12, 822375</b>	0
86	Androgen Receptor-Mediated Transcription in Prostate Cancer.. <b>2022, 11,</b>	1
85	BK002 Induces miR-192-5p-Mediated Apoptosis in Castration-Resistant Prostate Cancer Cells Modulation of PI3K/CHOP.. <b>2022, 12, 791365</b>	0
84	Non-metastatic castration-resistant prostate cancer: management recommendations.. <b>2022,</b>	
83	Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient.. <b>2022, 1</b>	
82	Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer.. <b>2022, 82, 31-31</b>	0
81	Novel insights into the anti-cancer effects of 3-bromopyruvic acid against castration-resistant prostate cancer.. <b>2022, 923, 174929</b>	
80	Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan.. <b>2021, 1-10</b>	
79	The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.. <b>2021, 23,</b>	3

- 78 Roles of Key Epigenetic Regulators in the Gene Transcription and Progression of Prostate Cancer.. **2021**, 8, 743376
- 77 A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8 T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice.. **2022**, 14,
- 76 The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. **2022**, 2, 74-92
- 75 Data\_Sheet\_1.PDF. **2020**,
- 74 The cost impact of disease progression to metastatic castration-sensitive prostate cancer.. **2022**, 28, 544-554
- 73 Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.. **2022**, 22, 470
- 72 Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer.. **2022**, 11,
- 71 Pharmacoeconomic evaluation of using enzalutamide for treatment of patients with metastatic hormone-sensitive prostate cancer. **2022**, 18, 90-105
- 70 Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure Preliminary Evidence of Pilot Experience. **2022**, 14, 2691 ○
- 69 Identification of Novel Pyroptosis-Related Gene Signatures to Predict Prostate Cancer Recurrence. **2022**, 12, ○
- 68 Non-metastatic castration-resistant prostate cancer: the evolving treatment landscape and role of nurse specialists. **2022**, 31, S4-S13
- 67 A Systematic Review of the Treatment Outcomes among Prostate Cancer Patients in Africa. 1-11
- 66 An appraisal of genetic testing for prostate cancer susceptibility. **2022**, 6, ○
- 65 Radium-223 for Metastatic Castrate-Resistant Prostate Cancer. **2022**, 12, 312-316
- 64 Continuous IV infusion of 5-flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. **2022**,
- 63 Isolation and Characterization of Urinary Extracellular Vesicles from Healthy Donors and Patients with Castration-Resistant Prostate Cancer. **2022**, 23, 7134 ○
- 62 How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?. **2022**, 32, 32/6S43-32/6S53
- 61 Conceptual assessment of HRQOL among Japanese non-metastatic castration-resistant prostate cancer ( nmCRPC ) patients.

- 60 Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacology. 10, e13481
- 59 A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis.
- 58 Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives. 10, 0
- 57 Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. 2022, 176, 106254
- 56 Evaluation of 11 C-choline positron emission tomography/computed tomography for determining treatment response in castration-resistant prostate cancer patients.
- 55 Epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. 2022, 18, 111-122
- 54 Interplay of Developmental Hippo/Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer. 2022, 11, 2449 0
- 53 A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer. 0
- 52 Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer. 0
- 51 The application of 3D bioprinting in urological diseases. 2022, 16, 100388 0
- 50 Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications. 2022, 255-275 0
- 49 Role of Interleukin-1 family in bone metastasis of prostate cancer. 12, 0
- 48 Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions. 2022, 18, 601-613 1
- 47 Factors Influencing Outcome PostRadium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges. 0
- 46 Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models. 0
- 45 A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications. 2022, 6, 100084 0
- 44 Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin. 2022, 23, 13003 1
- 43 Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/ECatenin Signaling by XAV939. 2022, 23, 12837 1

42	Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis. <b>2022,</b>	0
41	<b>177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art.</b>	1
40	Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC). <b>2022, 22,</b>	0
39	Stroma biglycan expression can be a prognostic factor in prostate cancers.	0
38	<b>177Lu-PSMA-617 RLT en mCRPC: experiencia de un solo centro, cuanto antes podr� ser mejor. 2022,</b>	0
37	Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. <b>2022, 23, 1398-1408</b>	0
36	Targeted therapy using astatine ( <sup>211</sup> At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.	0
35	Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel. <b>12,</b>	0
34	Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. <b>2022, 29, 8626-8637</b>	0
33	IL-1 $\beta$ expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.	0
32	A population-based study of factors associated with systemic treatment in advanced prostate cancer decedents.	1
31	Differentially expressed AC077690.1, AL049874.3 and AP001037.1 lncRNAs in prostate cancer. <b>2022, 74, 359-366</b>	0
30	Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. <b>2022,</b>	0
29	Identifying new driver genes for castration resistance for prostate cancer based on protein mass spectrometry and transcriptome big data.	0
28	A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [ <sup>177</sup> Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial. <b>2022, 14, 6225</b>	0
27	The Androgen Regulated lncRNA NAALADL2-AS2 Promotes Tumor Cell Survival in Prostate Cancer. <b>2022, 8, 81</b>	0
26	Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy. <b>2023, 115110</b>	0
25	Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. <b>2023, 247, 115077</b>	0

- 24 A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents. **2023**, 24, 2532 1
- 23 Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer. 0
- 22 Applications of proteomics in cancer diagnosis. **2023**, 257-285 0
- 21 Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells. **2023**, 866, 147330 0
- 20 Voluntarily wheel running inhibits the growth of CRPC xenograft by inhibiting HMGB1 in mice. **2023**, 174, 112118 0
- 19 Current and emerging approaches to noncompetitive AR inhibition. 0
- 18 The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer. **2023**, 14, 101417 0
- 17 PI3K/AKT/mTOR signaling supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition. **2023**, 9, 0
- 16 Combination of [68Ga]Ga-PSMA PET/CT and [18F]FDG PET/CT in demonstrating dedifferentiation in castration-resistant prostate cancer. **2023**, 0
- 15 Utilizing mixture design response surface methodology to determine effective combinations of plant derived compounds as prostate cancer treatments. **2023**, 6, 0
- 14 Monoamine oxidase A: An emerging therapeutic target in prostate cancer. 13, 0
- 13 Megakaryocyte-Derived IL-8 Acts as a Paracrine Factor for Prostate Cancer Aggressiveness through CXCR2 Activation and Antagonistic AR Downregulation. **2023**, 31, 210-218 0
- 12 Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer. **2023**, 21, 0
- 11 Costs of radium-223 and the pharmacy preparation 177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitals. **2023**, 26, 366-375 0
- 10 Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. **2023**, 24, 4601 0
- 9 Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data. **2023**, 83, 729-739 0
- 8 Epregrin expression and secretion is increased in castration-resistant prostate cancer. 13, 0
- 7 A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer. 13, 0

- 6 Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with 177 Lu-PSMA-617. A single-center prospective observational study. **2023**, 83, 792-800 ○
- 5 The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue. **2023**, 13, ○
- 4 Therapy results of patients with metastatic castration-resistant prostate cancer. Regional experience. **2023**, 10, 78-89 ○
- 3 Pyrogallol from *Spirogyra neglecta* Inhibits Proliferation and Promotes Apoptosis in Castration-Resistant Prostate Cancer Cells via Modulating Akt/GSK-3 $\beta$ /E-catenin Signaling Pathway. **2023**, 24, 6452 ○
- 2 Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer. 11, e15013 ○
- 1 Use of PARP inhibitors in prostate cancer: from specific to broader application. 14, ○